Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized Trial to Investigate AR201 for the Treatment of an Egg Allergy

Trial Profile

A Phase 2, Randomized Trial to Investigate AR201 for the Treatment of an Egg Allergy

Planning
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs AR-201 (Primary)
  • Indications Food hypersensitivity
  • Focus Therapeutic Use
  • Sponsors Aimmune Therapeutics
  • Most Recent Events

    • 04 Jan 2019 According to an Aimmune Therapeutics media release, the company has entered into a $170 million loan agreement with an affiliate of KKR.This financing secures resources to support the continued advancement of the pipeline of additional food allergy treatments, including this trial.
    • 04 Jan 2019 According to an Aimmune Therapeutics media release, the company has filed an IND application for AR201, for the treatment of egg allergy and intends to start this trial in first half of 2019.
    • 08 Aug 2018 According to an Aimmune Therapeutics media release, the company expect to submit an investigational new drug (IND) application for AR201 in egg allergy by the year end.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top